TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32317004

Group type: EXPERIMENTAL
Intervention: Vitamin C, Thiamine and Steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32318062

Group type: EXPERIMENTAL
Intervention: CCR4 targeting intervention, details on dosage and duration not available
Number of subjects: 0
Study: 32318268

Group type: EXPERIMENTAL
Intervention: High-dose meropenem (2-g infusion over 3 h every 8 h)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard-dose meropenem (1-g infusion over 3 h every 8 h)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: High-dose meropenem
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard-dose meropenem
Number of subjects: 78
Study: 32318271

Group type: EXPERIMENTAL
Intervention: ThrIVe-B programme (psychological therapy)
Number of subjects: 12
Study: 32318562

Group type: EXPERIMENTAL
Intervention: Intraneural (invasive) sensory feedback
Number of subjects: 1

Group type: COMPARATOR
Intervention: Electro-tactile (non-invasive) stimulation
Number of subjects: 1
Study: 32318621

Group type: EXPERIMENTAL
Intervention: Blarcamesine (ANAVEX2-73), a selective sigma-1 receptor agonist, administered over a 57-week Phase 2a trial.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Blarcamesine (ANAVEX2-73)
Number of subjects: 21
Study: 32318641

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 981

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 981
Study: 32318647

Group type: EXPERIMENTAL
Intervention: MLE4901 (NK3R antagonist)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 32319040

Group type: EXPERIMENTAL
Intervention: Posaconazole 300 mg twice daily on day 1 and then once daily for up to 28 days
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Posaconazole 300 mg tablet
Number of subjects: 65
Study: 32319144

Group type: EXPERIMENTAL
Intervention: Dietary supplements (DSs), average 9.12 (SD = 6.46) prescription drugs daily, 25 of 40 participants (62.5%) reported taking ≥1 DS daily.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (part of clinical trial), specific dosage and duration not mentioned.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned).
Number of subjects: 40
Study: 32319960

Group type: EXPERIMENTAL
Intervention: Radioembolization with 90Y resin microspheres
Number of subjects: 1047
Study: 32320048

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg every 2 weeks for up to 2 years)
Number of subjects: 25
Study: 32320798

Group type: EXPERIMENTAL
Intervention: Altis Single-Incision Sling System (SIS)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Standard midurethral transobturator and/or retropubic slings
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Altis SIS
Number of subjects: 355

Group type: COMPARATOR
Intervention: Comparator group (standard slings)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Altis SIS and standard slings
Number of subjects: 355
Study: 32321635

Group type: EXPERIMENTAL
Intervention: Old and new antirheumatic drugs
Number of subjects: 0
Study: 32322227

Group type: EXPERIMENTAL
Intervention: Child and Adolescent Dispositions Model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32322289

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (POMj) supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 32322662

Group type: EXPERIMENTAL
Intervention: Adenovirus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccinia virus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Herpes simplex virus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reovirus
Number of subjects: 0
Study: 32322811

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) kits; 4 kits provided to peers/partners.
Number of subjects: 287

Group type: COMPARATOR
Intervention: HIV Counseling and Testing (HCT) at local clinics; standard of care.
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Choice of either clinic-based HCT or HIV self-testing (HIVST) kits; 4 HCT invitations provided to peers/partners.
Number of subjects: 287
Study: 32323007

Group type: EXPERIMENTAL
Intervention: Strattice™ (PADM) placement
Number of subjects: 27
Study: 32323174

Group type: EXPERIMENTAL
Intervention: College students
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Elementary school students
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Formal education and mass media
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Internet and family experience
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Family discussion
Number of subjects: 381
Study: 32323217

Group type: EXPERIMENTAL
Intervention: Family Psychoeducation (FPE) Fidelity Scale
Number of subjects: 5
Study: 32323313

Group type: EXPERIMENTAL
Intervention: Functional competence on PASS (Cognitively Mediated Instrumental Activities of Daily Living)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Functional competence on PASS
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Functional competence on PASS combined with neurocognitive tests
Number of subjects: 137
Study: 32324008

Group type: EXPERIMENTAL
Intervention: Sessions with less silence
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sessions with more silence
Number of subjects: 21
Study: 32324916

Group type: EXPERIMENTAL
Intervention: Organised inpatient (stroke unit) care
Number of subjects: 5902

Group type: COMPARATOR
Intervention: Stroke ward care
Number of subjects: 5902

Group type: COMPARATOR
Intervention: Mobile stroke team care
Number of subjects: 5902

Group type: COMPARATOR
Intervention: Mixed rehabilitation ward care
Number of subjects: 5902
Study: 32324927

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (3, 10, and 20 mg/kg every 2 weeks)
Number of subjects: 23
Study: 32324981

Group type: EXPERIMENTAL
Intervention: Revefenacin 175 µg + Formoterol 20 µg
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo + Formoterol 20 µg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Revefenacin + Formoterol (combined administration)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Formoterol alone (evening administration)
Number of subjects: 122
Study: 32325004

Group type: EXPERIMENTAL
Intervention: Early Inspiratory Effort Assessment by Esophageal Manometry
Number of subjects: 0
Study: 32325037

Group type: EXPERIMENTAL
Intervention: MVA-MERS-S vaccine
Number of subjects: 0
Study: 32325043

Group type: EXPERIMENTAL
Intervention: NOACs (nonvitamin K antagonist oral anticoagulants)
Number of subjects: 6095

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 6095

Group type: EXPERIMENTAL
Intervention: Parenteral anticoagulation only
Number of subjects: 6095

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 6095

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 6095

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 6095

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 6095

Group type: COMPARATOR
Intervention: NOACs
Number of subjects: 6095
Study: 32325171

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant (ASCT) followed by nonmyeloablative allogeneic stem cell transplant (alloSCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose melphalan (200 mg/m2) for conditioning prior to ASCT
Number of subjects: 0
Study: 32325220

Group type: EXPERIMENTAL
Intervention: SC-003 antibody Fab fragment
Number of subjects: 0

Group type: COMPARATOR
Intervention: DPEP3
Number of subjects: 0
Study: 32325432

Group type: EXPERIMENTAL
Intervention: Aeonose electronic nose
Number of subjects: 0
Study: 32325461

Group type: EXPERIMENTAL
Intervention: Post-Transplantation Cyclophosphamide (PTCy) and Ruxolitinib (45 mg from day-7 to day-2, 15 mg from day+5 to day+100)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Post-Transplantation Cyclophosphamide (PTCy) and Ruxolitinib
Number of subjects: 20
Study: 32325480

Group type: EXPERIMENTAL
Intervention: GSK3050002 at 30 mg/kg/week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK3050002 at 300 mg/kg/week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK3050002 (both dosages)
Number of subjects: 0
Study: 32325487

Group type: EXPERIMENTAL
Intervention: Saturated fat ingestion
Number of subjects: 38

Group type: COMPARATOR
Intervention: Lean control subjects
Number of subjects: 38
Study: 32325849

Group type: EXPERIMENTAL
Intervention: Presence of the rs3749474 polymorphism of the CLOCK gene
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Dietary variables analyzed
Number of subjects: 898
Study: 32326881

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid analysis (CSF)
Number of subjects: 372
Study: 32327071

Group type: EXPERIMENTAL
Intervention: Early complications (≤30 days)
Number of subjects: 2811

Group type: EXPERIMENTAL
Intervention: Early complications, pneumothorax, pocket hematoma
Number of subjects: 2811

Group type: EXPERIMENTAL
Intervention: Device infection
Number of subjects: 2811

Group type: EXPERIMENTAL
Intervention: All CIED-related complications
Number of subjects: 2811

Group type: EXPERIMENTAL
Intervention: Early complications
Number of subjects: 2811
Study: 32327102

Group type: EXPERIMENTAL
Intervention: Surgical treatment (n=7)
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Medical treatment (n=29)
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Primary Aldosteronism (PA) patients
Number of subjects: 1020
Study: 32327472

Group type: EXPERIMENTAL
Intervention: TAK-659, 60-120 mg, once-daily oral administration in 28-day cycles until disease progression or unacceptable toxicity
Number of subjects: 105
Study: 32327479

Group type: EXPERIMENTAL
Intervention: Combined anatomical imaging with CT and/or MR with positron emission tomography (PET) using a novel second-generation prostate-specific membrane antigen (PSMA) probe
Number of subjects: 75
Study: 32327936

Group type: EXPERIMENTAL
Intervention: Electronic Foot Health Promotion Programme (FHPP) for 4 weeks
Number of subjects: 37
Study: 32328115

Group type: EXPERIMENTAL
Intervention: Omalizumab 8 mg/kg per month (n=36)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Omalizumab 16 mg/kg per month (n=36)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (n=18)
Number of subjects: 90
Study: 32328307

Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA) 30g/day for 12 weeks
Number of subjects: 40
Study: 32328440

Group type: EXPERIMENTAL
Intervention: New in Town intervention
Number of subjects: 0
Study: 32328500

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: VQ-SPECT
Number of subjects: 0
Study: 32328660

Group type: EXPERIMENTAL
Intervention: Tepotinib 215, 300 or 500 mg once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tepotinib 500 mg once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tepotinib
Number of subjects: 12
Study: 32328893

Group type: EXPERIMENTAL
Intervention: Patients with gastroparetic symptoms
Number of subjects: 43
Study: 32328953

Group type: EXPERIMENTAL
Intervention: Combination therapy with linagliptin and metformin (500 mg)
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Combination therapy with linagliptin and metformin (1000 mg)
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Metformin alone (500 mg)
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Metformin alone (1000 mg)
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 1160
Study: 32328976

Group type: EXPERIMENTAL
Intervention: Ibrutinib treatment
Number of subjects: 89
Study: 32329093

Group type: EXPERIMENTAL
Intervention: Fractional CO treatment
Number of subjects: 18
Study: 32329200

Group type: EXPERIMENTAL
Intervention: Postdilatation with NC-balloons (diameter 3.6±0.6 mm, inflation pressure 19.3±2.0 atm)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Postdilatation with NC-balloons
Number of subjects: 32
Study: 32329527

Group type: EXPERIMENTAL
Intervention: Lacosamide as add-on therapy
Number of subjects: 93
Study: 32329658

Group type: EXPERIMENTAL
Intervention: Gore Viabahn Balloon-Expandable Endoprosthesis (VBX Stent-Graft)
Number of subjects: 134
Study: 32330099

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy and intraventricular methotrexate
Number of subjects: 158

Group type: COMPARATOR
Intervention: Local radiotherapy
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Group 4 disease
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Group 3 patients
Number of subjects: 158
Study: 32330102

Group type: EXPERIMENTAL
Intervention: Omission of peg-filgrastim during dose-dense paclitaxel regimen
Number of subjects: 125
Study: 32330231

Group type: EXPERIMENTAL
Intervention: Elvitegravir/cobicistat
Number of subjects: 14
Study: 32330232

Group type: EXPERIMENTAL
Intervention: Ultra-processed food (UPF) consumption categorized into quartiles (low, medium-low, medium-high, and high consumption)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Higher consumption of UPF (>3 servings/d)
Number of subjects: 886
Study: 32330242

Group type: EXPERIMENTAL
Intervention: Pexidartinib (PLX3397) at doses of 800 to 5000 mg per day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pexidartinib (PLX3397) at doses of ≥2000 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pexidartinib (PLX3397) overall
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pexidartinib (PLX3397) in dose expansion
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pexidartinib (PLX3397) for responders with complete remission
Number of subjects: 90
Study: 32330241

Group type: EXPERIMENTAL
Intervention: ATRA plus arsenic trioxide (ATO) plus gemtuzumab ozogamicin (GO)
Number of subjects: 70
Study: 32330244

Group type: EXPERIMENTAL
Intervention: Eltrombopag (EPAG) administered at doses escalating from 50 to 300 mg/d.
Number of subjects: 34
Study: 32330305

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 RNA detection in urine specimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 RNA detection in blood specimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 RNA detection in anal swabs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 RNA detection in oropharyngeal swabs
Number of subjects: 0
Study: 32330510

Group type: EXPERIMENTAL
Intervention: Gliclazide modified release (MR), taken once daily for 14-18 weeks.
Number of subjects: 1244
Study: 32330879

Group type: EXPERIMENTAL
Intervention: Elective craniotomy
Number of subjects: 1452
Study: 32331767

Group type: EXPERIMENTAL
Intervention: BRCA positive women after chemotherapy treatment
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: BRCA negative women after chemotherapy treatment
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Untested/low risk controls after chemotherapy treatment
Number of subjects: 108

Group type: COMPARATOR
Intervention: Before chemotherapy treatment AMH levels in BRCA positive and negative women
Number of subjects: 108
Study: 32331936

Group type: EXPERIMENTAL
Intervention: Alirocumab 40 mg (<50 kg) or 75 mg (≥50 kg) every 2 weeks (Q2W)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg (<50 kg) or 300 mg (≥50 kg) every 4 weeks (Q4W)
Number of subjects: 42
Study: 32332141

Group type: EXPERIMENTAL
Intervention: Motorised PowerSpiral Enteroscopy (PSE)
Number of subjects: 132
Study: 32332461

Group type: EXPERIMENTAL
Intervention: Cohort 2 (with involuntary movements confirmed as possible TD)
Number of subjects: 739

Group type: COMPARATOR
Intervention: Cohort 1 (without involuntary movements or with non-TD involuntary movements)
Number of subjects: 739
Study: 32333207

Group type: EXPERIMENTAL
Intervention: Children living with HIV who do not know their status
Number of subjects: 435
Study: 32333591

Group type: EXPERIMENTAL
Intervention: Donepezil (Cholinesterase Inhibitor) started at 5 mg daily, increased to 10 mg daily if tolerated, maintained for 52 weeks.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Change in UPSIT score from 0 to 8 weeks with Donepezil treatment.
Number of subjects: 100
Study: 32333733

Group type: EXPERIMENTAL
Intervention: Aquablation procedure
Number of subjects: 101
Study: 32333763

Group type: EXPERIMENTAL
Intervention: High-protein diet (HP: 25:45:30% energy from protein:carbohydrate:fat)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Medium protein diet (MP: 15:55:30% of energy from protein:carbohydrate:fat)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Endocannabinoid concentrations (AEA, OEA, PEA, PREG)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Endocannabinoid 2-AG
Number of subjects: 38
Study: 32333853

Group type: EXPERIMENTAL
Intervention: Warfarin for 18 months after initial 6 months treatment
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo for 18 months after initial 6 months treatment
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Addition of PVOI to HERDOO2, DASH, and updated Vienna scores
Number of subjects: 371
Study: 32333930

Group type: EXPERIMENTAL
Intervention: Sleep Efficiency (SE)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Total Sleep Time (TST)
Number of subjects: 209
Study: 32334566

Group type: EXPERIMENTAL
Intervention: Preoperative serum HDL < 1.03 mmol/L
Number of subjects: 74284

Group type: COMPARATOR
Intervention: Preoperative serum HDL > 1.03 mmol/L
Number of subjects: 74284

Group type: EXPERIMENTAL
Intervention: HDL levels categorized as < 0.96, 1.14-1.35, > 1.35
Number of subjects: 74284
Study: 32335306

Group type: EXPERIMENTAL
Intervention: Investigational unitary manifold (UM) stent graft system
Number of subjects: 44
Study: 32335374

Group type: EXPERIMENTAL
Intervention: Vorolanib 200 mg plus everolimus 5 mg once daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Vorolanib 100 mg plus everolimus 5 mg once daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Vorolanib 150 mg plus everolimus 5 mg once daily
Number of subjects: 22
Study: 32335423

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 996
Study: 32335515

Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Myocardial Feature Tracking
Number of subjects: 0
Study: 32335525

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (measured as VO2peak during a graded cycle ergometer test)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (VO2peak)
Number of subjects: 30
Study: 32335895

Group type: EXPERIMENTAL
Intervention: Vaginal cleansing with povidone-iodine or chlorhexidine solution
Number of subjects: 7038
Study: 32336486

Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale
Number of subjects: 2393
Study: 32336984

Group type: EXPERIMENTAL
Intervention: Community-based recovery-oriented care delivered by trained multidisciplinary community mental health teams.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Care as usual (CAU) - institutional, hospital-based mental health care.
Number of subjects: 180
Study: 32336987

Group type: EXPERIMENTAL
Intervention: EMOTION intervention (transdiagnostic indicated preventive cognitive behavioral therapy)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 795
Study: 32337054

Group type: EXPERIMENTAL
Intervention: anti-TNFα therapy
Number of subjects: 310
Study: 32337059

Group type: EXPERIMENTAL
Intervention: 1.8 g/day of phosphatidylcholine (PPC) as adjunctive treatment to standard care
Number of subjects: 2843
Study: 32337094

Group type: EXPERIMENTAL
Intervention: Erlotinib, cetuximab, and bevacizumab (triplet combination)
Number of subjects: 36
Study: 32337122

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no music)
Number of subjects: 0
Study: 32337475

Group type: EXPERIMENTAL
Intervention: 22 g freeze-dried blueberries for 8 weeks
Number of subjects: 52
Study: 32337496

Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Physician's Choice of Chemotherapy (PCT)
Number of subjects: 431
Study: 32337789

Group type: EXPERIMENTAL
Intervention: Art interventions conducted by professional art pedagogues
Number of subjects: 7
Study: 32338094

Group type: EXPERIMENTAL
Intervention: Combined inhalers (ICS + LABA)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Emergency Room visits
Number of subjects: 69

Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Asthma-related quality-of-life
Number of subjects: 69
Study: 32338117

Group type: EXPERIMENTAL
Intervention: Higher carotid artery β-stiffness index
Number of subjects: 84
Study: 32338433

Group type: EXPERIMENTAL
Intervention: rAHF 2 mL prophylaxis
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: rAHF 2 mL treatment
Number of subjects: 65
Study: 32338538

Group type: EXPERIMENTAL
Intervention: Incentive sensitization for exercise reinforcement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32338562

Group type: EXPERIMENTAL
Intervention: Panobinostat
Number of subjects: 0
Study: 32338619

Group type: EXPERIMENTAL
Intervention: PERSPeCT tailored messaging system (up to 30 emailed messages over 65 days)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: PERSPeCT tailored messaging system
Number of subjects: 119

Group type: COMPARATOR
Intervention: Historical cohort of white people who smoke (control group)
Number of subjects: 119
Study: 32338621

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program driven by a tablet app and remote coaching (12-week program, exercises at least 5 days a week)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program driven by a tablet app and remote coaching
Number of subjects: 15

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 15
Study: 32339189

Group type: EXPERIMENTAL
Intervention: Durvalumab monotherapy
Number of subjects: 188
Study: 32339337

Group type: EXPERIMENTAL
Intervention: Detailed routine ultrasound examination
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Targeted prenatal imaging in known cases of fetal infection
Number of subjects: 255

Group type: COMPARATOR
Intervention: Non-specific infection-related ultrasound findings
Number of subjects: 255
Study: 32339368

Group type: EXPERIMENTAL
Intervention: Yescarta (axicabtagene ciloleucel)
Number of subjects: 0
Study: 32340508

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study: 32340734

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided brachial plexus block
Number of subjects: 565
Study: 32341039

Group type: EXPERIMENTAL
Intervention: 24-h fasting
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mild cold exposure (COLD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thermoneutrality (24°C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mild cold (19°C)
Number of subjects: 20